企業プロフィール
Biogen 株価・ニュース・カタリスト
- ティッカー:
- BIIB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
209.15 USD (-0.32%)
終値
最終更新: 2026年8月17日
27.9B USD
時価総額
株価変動の要因
As of Aug 17, 2026, BIIB closed down 0.32% at $209.15. No new same-company headline was identified in the current news window.
企業概要
事業概要
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.
所在地とセクター分類
Biogen is headquartered in the United States and listed on NASDAQ. It sits in large-cap biotechnology with a neuroscience identity.
ビジネスモデルの特徴
The company generates value through product sales, lifecycle management, and ongoing R&D in difficult CNS and rare-disease areas. Investors watch launch execution, pipeline progress, and franchise durability.
バイオ業界での位置付け
Biogen occupies one of the most important large-cap neuroscience positions in biotech. It is far less binary than a small-cap name, but major pipeline and label events still matter a lot.
今後のカタリスト
- Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。